Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF165 Neutralization
Authors
Keywords
-
Journal
Marine Drugs
Volume 16, Issue 4, Pages 113
Publisher
MDPI AG
Online
2018-04-03
DOI
10.3390/md16040113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis
- (2017) Marina Kovaleva et al. Frontiers in Immunology
- How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches
- (2016) Vibhuti Agrahari et al. Expert Opinion on Drug Delivery
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting VEGF in eye neovascularization: What's new?
- (2016) Marialaura Amadio et al. PHARMACOLOGICAL RESEARCH
- Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling
- (2015) Filippa Fleetwood et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Current phase 1/2 research for neovascular age-related macular degeneration
- (2015) Paula E. Pecen et al. CURRENT OPINION IN OPHTHALMOLOGY
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
- (2014) Ursula Schmidt-Erfurth et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development
- (2014) Marina Kovaleva et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview
- (2014) Francesco Semeraro et al. Expert Opinion On Drug Safety
- Shark Attack: High affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation
- (2014) Stefan Zielonka et al. JOURNAL OF BIOTECHNOLOGY
- Recent developments in the treatment of age-related macular degeneration
- (2014) Frank G. Holz et al. JOURNAL OF CLINICAL INVESTIGATION
- Structural insights and biomedical potential of IgNAR scaffolds from sharks
- (2014) Stefan Zielonka et al. mAbs
- Role of phospholipases A2 in diabetic retinopathy: In vitro and in vivo studies
- (2013) Gabriella Lupo et al. BIOCHEMICAL PHARMACOLOGY
- Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock
- (2013) Rafael Bojalil et al. BMC IMMUNOLOGY
- Evolving strategies in the management of diabetic macular edema: clinical trials and current management
- (2013) Benjamin J. Thomas et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
- (2013) K Ghasemi Falavarjani et al. EYE
- Human TNF cytokine neutralization with a vNAR fromHeterodontus franciscishark: A potential therapeutic use
- (2013) Tanya Camacho-Villegas et al. mAbs
- Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development
- (2013) Mostafa Hanout et al. Biomed Research International
- Anti-vascular endothelial growth factor therapy for diabetic macular edema
- (2013) David S. Boyer et al. Therapeutic Advances in Endocrinology and Metabolism
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
- (2012) Mischa R. Müller et al. mAbs
- Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) Vs Bevacizumab (Avastin)
- (2012) William Stevenson et al. Ocular Surface
- Acute Intraocular Inflammation Caused by Endotoxin after Intravitreal Injection of Counterfeit Bevacizumab in Shanghai, China
- (2012) Fenghua Wang et al. OPHTHALMOLOGY
- Ocular drug delivery: a clue from nanotechnology
- (2012) Claudio Bucolo et al. Frontiers in Pharmacology
- Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye
- (2011) J J Chen et al. EYE
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
- (2011) C H Meyer et al. EYE
- The PKCβ/HuR/VEGF pathway in diabetic retinopathy
- (2010) M. Amadio et al. BIOCHEMICAL PHARMACOLOGY
- Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study
- (2010) Davin Johnson et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)
- (2010) Michel Michaelides et al. OPHTHALMOLOGY
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
- (2009) Janusz Wesolowski et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)
- (2008) M Georgopoulos et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Therapeutic monoclonal antibodies in ophthalmology
- (2008) Eduardo B. Rodrigues et al. PROGRESS IN RETINAL AND EYE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started